Effects of two commonly used antidepressants amitriptyline and fluoxetine on the pharmacokinetics of abrocitinib in rats.

Autor: Chen L; The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China., Chen X; The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China., Liu J; The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; The Third Affiliated Hospital of Wenzhou Medical University, Zhejiang, China., Yang J; The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital), Zhejiang, China., Xu RA; The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China. Electronic address: xra@wmu.edu.cn.
Jazyk: angličtina
Zdroj: Chemico-biological interactions [Chem Biol Interact] 2024 Jul 01; Vol. 397, pp. 111041. Date of Electronic Publication: 2024 May 07.
DOI: 10.1016/j.cbi.2024.111041
Abstrakt: Abrocitinib is approved to treat moderate-to-severe atopic dermatitis and eliminated mainly through cytochrome P450 (CYP450) enzyme. Two commonly used antidepressants, amitriptyline and fluoxetine, could inhibit the activities of CYP2C19 and CYP3A4. In this study, we developed a new and quick ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for quantitatively analyzing the plasma concentration of abrocitinib, and further investigated the effects of amitriptyline or fluoxetine on the pharmacokinetics of abrocitinib in rats. The selectivity, linearity, recovery, accuracy, precision, matrix effect and stability of UPLC-MS/MS assay were satisfied according to the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines. Our result showed that when co-administered with amitriptyline and fluoxetine, the CLz/F of abrocitinib was reduced by 44.4 % and 33.3 %, respectively, while the AUC (0-t) of abrocitinib was increased by 77.7 % and 49.4 %, respectively. It indicated that amitriptyline and fluoxetine could significantly increase the plasma concentration of abrocitinib in rats. Thus, dose adjustment of abrocitinib may be required when it is combined with amitriptyline or fluoxetine in ongoing clinical practice.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: